"Khakoo Y" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Khakoo Y"' showing total 1,095 results

Start Over "Khakoo Y"

1,095 results on '"Khakoo Y"'

1. Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma-Safety and outcomes.

Author: Sait SF, Kernan NA, Klein E, Spitzer B, Levy CF, Fish J, Yildirim O, Haque S, Donzelli M, Bernot MR, Abramson DH, Francis JH, Khakoo Y, Karajannis M, Sands S, Pandit-Taskar N, Wolden S, Kramer K, and Dunkel IJ
Subjects: Humans, Male, Female, Retrospective Studies, Child, Preschool, Child, Infant, Combined Modality Therapy, Survival Rate, Central Nervous System Neoplasms therapy, Central Nervous System Neoplasms mortality, Retinal Neoplasms therapy, Retinal Neoplasms pathology, Retinal Neoplasms mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Adolescent, Follow-Up Studies, Stem Cell Transplantation, Prognosis, Induction Chemotherapy, Hematopoietic Stem Cell Transplantation methods, Craniospinal Irradiation methods, Radioimmunotherapy methods, Retinoblastoma therapy, Retinoblastoma pathology, Retinoblastoma mortality, Transplantation, Autologous
Abstract: Background: The prognosis for patients with central nervous system (CNS) retinoblastoma (RB) (trilateral or stage 4b metastatic RB) treated with high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) remains poor. The impact of irradiation when administered as part of upfront therapy post HDC-ASCT on treatment outcomes and survival is unknown., Methods: We performed a retrospective review of all patients with CNS RB (seven stage 4b, eight trilateral, one pineal lesion belonging to methylation group RB) who underwent induction chemotherapy with an intent to proceed to HDC-ASCT at two institutions., Results: Twelve of 16 patients (n = 75%) achieved an objective response to induction chemotherapy, while four patients had progressive/refractory disease; two patients responded to subsequent therapy and proceeded to ASCT, and two patients did not. Seven of 14 patients who underwent HDC-ASCT, received radiotherapy as part of upfront therapy post HDC-ASCT in the form of craniospinal irradiation (CSI) (n = 3), intraventricular radioimmunotherapy (n = 3), or both CSI and intraventricular radioimmunotherapy (n = 1). The Kaplan-Meier estimate of overall survival for these patients was 62.5% at 5 years; no patients developed second malignant neoplasms within the radiation fields. For the seven patients who did not receive radiotherapy, the overall survival was 28.6% at 5 years., Conclusions: CSI (23.4 Gy) alone or in conjunction with intraventricular RIT may have clinical utility in eliminating persistent MRD post HDC-ASCT, contributing to improved disease-free survival in patients with CNS RB. This treatment strategy merits evaluation in a prospective, multicenter clinical trial for patients with CNS metastatic RB., (© 2024 Wiley Periodicals LLC.)
Published: 2024
Full Text: View/download PDF

2. Analysis of Gender Discrepancies in Leadership Roles and Recognition Awards in the Child Neurology Society.

Author: Martindale JM, Christy AL, Gombolay GY, Aravamuthan BR, Jansen L, Joshi S, Strober JB, Terrell M, Tilton AH, Pearl PL, Silver JK, Mink JW, and Khakoo Y
Subjects: Humans, Female, Male, Retrospective Studies, Sexism, Pediatrics, Leadership, Awards and Prizes, Neurology, Societies, Medical, Physicians, Women statistics & numerical data
Abstract: Background and Objectives: Gender disparities have been demonstrated across several medical specialties, including neurology. Although women have comprised most of the child neurology trainees since 2007, it is not apparent whether this demographic shift is reflected in the Child Neurology Society (CNS) awards and leadership. This study aimed to evaluate the differences in gender representation among leadership positions and award recipients within the CNS. The primary outcome measure was the total number of board of director (BOD) positions or awards given by gender each year., Methods: A retrospective review of publicly available data was conducted on CNS members, post-training award recipients, and BOD positions, including nomination records, from 1972 to 2023. Data abstracted were restricted to gender to preserve member and nominee anonymity. Gender identification and consensus were determined through a combination of strategies and study members. Data analysis included descriptive statistics, Pearson χ 2 test, and the exact binomial test to compare gender proportions and the probability of being underrepresented in awards, leadership, and nominations over time. Data are presented according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines., Results: From 1972 to 2023, women represented 29% (44/152) of the BOD positions and 26% (61/236) of post-training award recipients presented by the CNS. Despite the increase in the proportion of women in child neurology, the overall gap in gender representation in leadership positions remains broadly stable. Only 13% (4/32) of CNS presidents have been women, a significant underrepresentation (95% CI 2.3%-52%, p < 0.004), although the representation of women in nonpresidential positions increased from 2003 to 2023. Women are also underrepresented as overall awardees (95% CI 12%-38%, p < 0.00001) except for the Philip R. Dodge Young Investigator Award, which is an investigator-initiated application., Discussion: Women remain underrepresented at the highest levels of recognition in child neurology despite representing most of the field. Reasons for disparities are known to be multifactorial and likely include gender bias and structural sexism. We present several discussion topics that seek to rationalize this disparity and provide suggestions for improving diversity, equity, and inclusion for leadership roles and awards.
Published: 2024
Full Text: View/download PDF

3. Neurocutaneous Melanocytosis-Associated Hydrocephalus: The Memorial Sloan Kettering Experience from 2001 to 2022.

Author: Rodriguez S, DeIeso-Frechette F, Umeasor C, Alli C, Azzi C, Haque S, Pugh JA, Meeker N, and Khakoo Y
Subjects: Humans, Female, Male, Membrane Proteins, GTP Phosphohydrolases genetics, Skin Neoplasms pathology, Skin Neoplasms complications, Infant, Prognosis, Child, Preschool, Child, Hydrocephalus etiology, Hydrocephalus pathology, Neurocutaneous Syndromes pathology, Neurocutaneous Syndromes complications, Melanoma pathology, Melanoma complications, Melanosis pathology, Melanosis etiology, Ventriculoperitoneal Shunt
Abstract: We report two neurocutaneous melanocytosis (NCM) patients who required ventriculoperitoneal shunt placement and subsequently developed intraperitoneal melanoma. These patients with NCM are at an increased risk for developing NRAS-associated melanomas in the central nervous system, which in turn may lead to symptomatic hydrocephalus requiring cerebrospinal fluid diversion. Due to the rarity of NCM, current knowledge on disease progression and appropriate management is limited. Ongoing studies aiming to better understand this condition and inform its clinical management may help to identify risk factors for developing more severe complications., (© 2024 Wiley Periodicals LLC.)
Published: 2025
Full Text: View/download PDF

4. Hypofractionated re-irradiation for diffuse intrinsic pontine glioma.

Author: Mankuzhy NP, Tringale KR, Dunkel IJ, Farouk Sait S, Souweidane MM, Khakoo Y, Karajannis MA, and Wolden S
Subjects: Adolescent, Child, Child, Preschool, Humans, Radiation Dose Hypofractionation, Steroids, Brain Stem Neoplasms radiotherapy, Diffuse Intrinsic Pontine Glioma radiotherapy, Re-Irradiation
Abstract: Background: Re-irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We report our institutional experience of reRT for DIPG, which includes hypofractionation (HF)., Methods: We reviewed pediatric patients treated with brainstem reRT for DIPG at our institution from 2012 to 2022. Patients were grouped by HF or CF. Outcomes included steroid use, and overall survival (OS) was measured from both diagnosis and start of reRT., Results: Of 22 patients who received reRT for DIPG, two did not complete their course due to clinical decline. Of the 20 who completed reRT, the dose was 20-30 Gy in 2-Gy fractions (n = 6) and 30-36 Gy in 3-Gy fractions (n = 14). Median age was 5 years (range: 3-14), median interval since initial RT was 8 months (range: 3-20), and 12 received concurrent bevacizumab. Median OS from diagnosis was 18 months [95% confidence interval: 17-24]. Median OS from start of reRT for HF versus CF was 8.2 and 7.5 months, respectively (p = .20). Thirteen (93%) in the HF group and three (75%) in the CF group tapered pre-treatment steroid dose down or off within 2 months after reRT due to clinical improvement. There was no significant difference in steroid taper between HF and CF (p = .4). No patients developed radionecrosis., Conclusion: reRT with HF achieved survival duration comparable to published outcomes and effectively palliated symptoms. Future investigation of this regimen in the context of new systemic therapies and upfront HF is warranted., (© 2024 Wiley Periodicals LLC.)
Published: 2024
Full Text: View/download PDF

5. Pediatric Neurology in the Post-Roe Era.

Author: Gano D, Agarwal S, and Khakoo Y
Subjects: Humans, Supreme Court Decisions, Pediatrics, Neurology, Abortion, Legal
Abstract: Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yasmin Khakoo is the Editor-in-Chief of Pediatric Neurology, and Sonika Agarwal serves on the editorial board of the journal. Sonika Agarwal reports a relationship with Child Neurology Foundation that includes board membership.
Published: 2023
Full Text: View/download PDF

6. Psychiatric manifestations as initial presentation for pediatric CNS germ cell tumors, a case series

Author: Malbari, F., Gershon, T. R., Garvin, J. H., Allen, J. C., Khakoo, Y., Levy, A. S., and Dunkel, I. J.
Published: 2016
Full Text: View/download PDF

7. Explainable Artificial Intelligence: Point and Counterpoint.

Author: Knox AT, Khakoo Y, and Gombolay G
Published: 2023
Full Text: View/download PDF

8. Pediatric Postmortem Tissue Donation in the Confines of a Pandemic: A Model of Collaboration.

Author: Arias-Stella EU, Campbell C, Pisapia DJ, Cocito C, McThenia S, Degliuomini M, Greenfield JP, and Khakoo Y
Subjects: Humans, Retrospective Studies, Male, Female, Child, Child, Preschool, Adolescent, Infant, Pandemics, SARS-CoV-2, COVID-19, Autopsy, Tissue and Organ Procurement
Abstract: Background: Obtaining postmortem tissue from pediatric oncology patients is critical to research and may help grieving families heal. Since 2019, the national Gift from a Child program has made significant progress in collecting postmortem tissue from pediatric patients with central nervous system tumors to advance research. This progress was at risk during the onset of the severe acute respiratory syndrome coronavirus 2 pandemic, when some autopsy programs came to a halt., Methods: We retrospectively reviewed autopsies of four patients treated at Memorial Sloan Kettering Cancer Center who underwent postmortem examination at Weill Cornell Medicine from June 2020 to March 2021. We collected patient demographics, Do not resuscitate status, time of death and procedure, restrictions due to the coronavirus disease 2019 (COVID-19) pandemic, and results of the tissue analysis., Results: Three of four specimens were processed within 12 hours of the time of death. Two families required interpreter services to obtain consent. In all cases, tumor aliquots were flash frozen for further study. Cell line generation was successful in one case. All families expressed gratitude both for the opportunity to participate and for the handling of the procedures., Conclusions: Despite the sensitive nature of these cases and the challenges presented by COVID-19 restrictions, clinicians should offer the option of a rapid autopsy to caregivers of pediatric patients based on the scientific need and the positive effect it has on grieving families. This article outlines the logistic efforts required for these donations to take place and provides a framework for providers to offer rapid autopsy as an option for families through this program., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Inc.)
Published: 2023
Full Text: View/download PDF

9. An International Pediatric-Onset Opsoclonus-Myoclonus Ataxia Syndrome Registry and Clinical Research Network: Development, Progress, and Vision.

Author: Kerr LM, Ryan ME, Lim M, Hearn S, Klein A, Deiva K, Hopkins SE, Bacchus MK, Sokol EA, Waanders AJ, Mitchell WG, Khakoo Y, Lotze TE, Zhang B, and Gorman MP
Subjects: Child, Humans, Ataxia complications, Opsoclonus-Myoclonus Syndrome
Abstract: Competing Interests: Declaration of competing interest Dr. Andrea Klein has participated in advisory board meetings for several pharmaceutical companies, including Biogen, Novartis Gene Therapies, PTC, Pfizer, and Roche. She has also received speakers honoraria from Novartis Gene Therapies, Pfizer, and Roche. Dr. Sarah E. Hopkins received salary support from the US Centers for Disease Control for her work related to AFM surveillance. Additionally, she was the site PI for a clinical trial for patients with 22q11.2 deletion syndrome, which was funded by Nobias Therapeutics. Dr. Elizabeth Sokol served on the scientific advisory board for YMabs Pharmaceuticals. Dr. Yasmin Khakoo received travel reimbursement from the OMSLife Foundation and Nevus Outreach, Inc. Dr. Mark Gorman has received research funding from Roche and Genentech for research that is not related to OMAS, as well as from Pfizer for another OMAS project.
Published: 2023
Full Text: View/download PDF

10. You Can Run but You Can't Hide: Artificial Intelligence Is Here.

Author: Knox A, Bass N, and Khakoo Y
Published: 2023
Full Text: View/download PDF

11. Immunotherapy: DISCOVERY PROTEOMICS FOR ANALYTES TO PREDICT CYTOKINE RELEASE SYNDROME ON DAY OF INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS

Author: Lakkaraja, M., primary, Hosszu, K., additional, Mcavoy, D., additional, Mauguen, A., additional, Purdon, T.J., additional, Auchincloss, T., additional, Klein, E., additional, Khakoo, Y., additional, Santomasso, B., additional, Senechal, B., additional, Riviere, I., additional, Sadelain, M., additional, Curran, K.J., additional, Park, J., additional, Brentjens, R.J., additional, and Boelens, J.J., additional
Published: 2022
Full Text: View/download PDF

12. An unusual case of opsoclonus-myoclonus-ataxia syndrome associated neuroblastoma: High-risk disease requiring immunotherapy.

Author: Stiefel J, Basu E, Meyer R, Kaur G, and Khakoo Y
Subjects: Ataxia complications, Ataxia pathology, Humans, Infant, Male, Neuroblastoma complications, Neuroblastoma pathology, Opsoclonus-Myoclonus Syndrome complications, Opsoclonus-Myoclonus Syndrome pathology, Prognosis, Ataxia therapy, Immunotherapy methods, Neuroblastoma therapy, Opsoclonus-Myoclonus Syndrome therapy
Published: 2020
Full Text: View/download PDF

13. PREDICTORS FOR NEUROTOXICITY on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform

Author: Lakkaraja, M., primary, Hosszu, K., additional, Mcavoy, D., additional, Mauguen, A., additional, Purdon, T.J., additional, Auchincloss, T., additional, Klein, E., additional, Khakoo, Y., additional, Santomasso, B., additional, Senechal, B., additional, Riviere, I., additional, Sadelain, M., additional, Curran, K.J., additional, Park, J., additional, Brentjens, R.J., additional, and Boelens, J.J., additional
Published: 2021
Full Text: View/download PDF

14. Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.

Author: Miller AM, Szalontay L, Bouvier N, Hill K, Ahmad H, Rafailov J, Lee AJ, Rodriguez-Sanchez MI, Yildirim O, Patel A, Bale TA, Benhamida JK, Benayed R, Arcila ME, Donzelli M, Dunkel IJ, Gilheeney SW, Khakoo Y, Kramer K, Sait SF, Greenfield JP, Souweidane MM, Haque S, Mauguen A, Berger MF, Mellinghoff IK, and Karajannis MA
Subjects: Adolescent, Child, High-Throughput Nucleotide Sequencing, Humans, Mutation, Pathology, Molecular, Young Adult, Brain Neoplasms diagnosis, Brain Neoplasms genetics, Brain Neoplasms pathology, Cell-Free Nucleic Acids cerebrospinal fluid, Central Nervous System Neoplasms, Glioma genetics
Abstract: Background: Safe sampling of central nervous system tumor tissue for diagnostic purposes may be difficult if not impossible, especially in pediatric patients, and an unmet need exists to develop less invasive diagnostic tests., Methods: We report our clinical experience with minimally invasive molecular diagnostics using a clinically validated assay for sequencing of cerebrospinal fluid (CSF) cell-free DNA (cfDNA). All CSF samples were collected as part of clinical care, and results reported to both clinicians and patients/families., Results: We analyzed 64 CSF samples from 45 pediatric, adolescent and young adult (AYA) patients (pediatric = 25; AYA = 20) with primary and recurrent brain tumors across 12 histopathological subtypes including high-grade glioma (n = 10), medulloblastoma (n = 10), pineoblastoma (n = 5), low-grade glioma (n = 4), diffuse leptomeningeal glioneuronal tumor (DLGNT) (n = 4), retinoblastoma (n = 4), ependymoma (n = 3), and other (n = 5). Somatic alterations were detected in 30/64 samples (46.9%) and in at least one sample per unique patient in 21/45 patients (46.6%). CSF cfDNA positivity was strongly associated with the presence of disseminated disease at the time of collection (81.5% of samples from patients with disseminated disease were positive). No association was seen between CSF cfDNA positivity and the timing of CSF collection during the patient's disease course., Conclusions: We identified three general categories where CSF cfDNA testing provided additional relevant diagnostic, prognostic, and/or therapeutic information, impacting clinical assessment and decision making: (1) diagnosis and/or identification of actionable alterations; (2) monitor response to therapy; and (3) tracking tumor evolution. Our findings support broader implementation of clinical CSF cfDNA testing in this population to improve care., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2022
Full Text: View/download PDF

15. Adverse Effects of War and Armed Conflict on Children.

Author: Deputy SR, Khakoo Y, and Gospe SM Jr
Subjects: Child, Humans, Armed Conflicts
Published: 2022
Full Text: View/download PDF

16. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.

Author: Rossor T, Yeh EA, Khakoo Y, Angelini P, Hemingway C, Irani SR, Schleiermacher G, Santosh P, Lotze T, Dale RC, Deiva K, Hero B, Klein A, de Alarcon P, Gorman MP, Mitchell WG, and Lim M
Subjects: Ataxia complications, Child, Disease Progression, Humans, Internationality, Neuroblastoma diagnosis, Neuroblastoma drug therapy, Ocular Motility Disorders complications, Opsoclonus-Myoclonus Syndrome complications, Opsoclonus-Myoclonus Syndrome diagnosis, Opsoclonus-Myoclonus Syndrome therapy
Abstract: Background and Objectives: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare disorder of the nervous system that classically presents with a combination of characteristic eye movement disorder and myoclonus, in addition to ataxia, irritability, and sleep disturbance. There is good evidence that OMAS is an immune-mediated condition that may be paraneoplastic in the context of neuroblastoma. This syndrome may be associated with long-term cognitive impairment, yet it remains unclear how this is influenced by disease course and treatment. Treatment is largely predicated on immune suppression, but there is limited evidence to indicate an optimal regimen., Methods: Following an international multiprofessional workshop in 2004, a body of clinicians and scientists comprising the International OMS Study group continued to meet biennially in a joint professionals and family workshop focusing on pediatric OMAS. Seventeen years after publication of the first report, a writing group was convened to provide a clinical update on the definitions and clinical presentation of OMAS, biomarkers and the role of investigations in a child presenting with OMAS, treatment and management strategies including identification and support of long-term sequelae., Results: The clinical criteria for diagnosis were reviewed, with a proposed approach to laboratory and radiologic investigation of a child presenting with possible OMAS. The evidence for an upfront vs escalating treatment regimen was reviewed, and a treatment algorithm proposed to recognize both these approaches. Importantly, recommendations on monitoring of immunotherapy response and longer-term follow-up based on an expert consensus are provided., Discussion: OMAS is a rare neurologic condition that can be associated with poor cognitive outcomes. This report proposes an approach to investigation and treatment of children presenting with OMAS, based on expert international opinion recognizing the limited data available., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
Published: 2022
Full Text: View/download PDF

17. Editor-In-Chief.

Author: Khakoo Y
Subjects: Humans, Neurology, Pediatrics, Editorial Policies, Periodicals as Topic
Published: 2022
Full Text: View/download PDF

18. The Pediatric Neurology Trainee Publication Award.

Author: Khakoo Y, Brenton JN, Brumback AC, Desai J, Mytinger JR, Reese JJ Jr, and Scantlebury MH
Subjects: Humans, Awards and Prizes, Neurology education, Pediatrics education
Published: 2021
Full Text: View/download PDF

19. Neurocutaneous melanocytosis-associated malignant melanoma presenting with peritoneal seeding.

Author: Sener U, Elmore K, Jayaseelan K, Porter J, Marghoob A, Rosenblum MK, Haque S, and Khakoo Y
Subjects: Child, Female, Humans, Infant, Melanoma complications, Melanoma diagnosis, Melanosis diagnosis, Melanosis etiology, Neurocutaneous Syndromes complications, Neurocutaneous Syndromes diagnosis, Nevus, Pigmented diagnosis, Skin Neoplasms diagnosis
Abstract: Neurocutaneous melanocytosis (NCM) is characterized by melanocyte deposition in the leptomeninges and brain parenchyma, primarily occurring in children with large or giant congenital melanocytic nevi (LCMN) or multiple congenital melanocytic nevi. Patients with NCM may develop hydrocephalus and increased intracranial pressure, which can be managed with ventriculoperitoneal (VP) shunting. We present the case of a 16-month-old girl who developed peritoneal carcinomatosis and malignant ascites following VP shunting for hydrocephalus secondary to NCM to increase awareness of this rare, but serious, complication of cerebrospinal fluid diversion., (© 2021 Wiley Periodicals LLC.)
Published: 2021
Full Text: View/download PDF

20. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.

Author: Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, Khakoo Y, Karajannis MA, Woodling K, Palmer JD, Osorio DS, Leonard J, Abdelbaki MS, Madan-Swain A, Atkinson TP, Whitley RJ, Fiveash JB, Markert JM, and Gillespie GY
Subjects: Adolescent, Brain Neoplasms diagnostic imaging, Brain Neoplasms pathology, Brain Neoplasms radiotherapy, Child, Child, Preschool, Combined Modality Therapy, Female, Glioma diagnostic imaging, Glioma pathology, Glioma radiotherapy, Humans, Kaplan-Meier Estimate, Killer Cells, Natural, Leukocyte Count, Male, T-Lymphocytes, Brain Neoplasms therapy, Glioma therapy, Oncolytic Virotherapy adverse effects
Abstract: Background: Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue., Methods: We conducted a phase 1 trial of G207, which used a 3+3 design with four dose cohorts of children and adolescents with biopsy-confirmed recurrent or progressive supratentorial brain tumors. Patients underwent stereotactic placement of up to four intratumoral catheters. The following day, they received G207 (10 7 or 10 8 plaque-forming units) by controlled-rate infusion over a period of 6 hours. Cohorts 3 and 4 received radiation (5 Gy) to the gross tumor volume within 24 hours after G207 administration. Viral shedding from saliva, conjunctiva, and blood was assessed by culture and polymerase-chain-reaction assay. Matched pre- and post-treatment tissue samples were examined for tumor-infiltrating lymphocytes by immunohistologic analysis., Results: Twelve patients 7 to 18 years of age with high-grade glioma received G207. No dose-limiting toxic effects or serious adverse events were attributed to G207 by the investigators. Twenty grade 1 adverse events were possibly related to G207. No virus shedding was detected. Radiographic, neuropathological, or clinical responses were seen in 11 patients. The median overall survival was 12.2 months (95% confidence interval, 8.0 to 16.4); as of June 5, 2020, a total of 4 of 11 patients were still alive 18 months after G207 treatment. G207 markedly increased the number of tumor-infiltrating lymphocytes., Conclusions: Intratumoral G207 alone and with radiation had an acceptable adverse-event profile with evidence of responses in patients with recurrent or progressive pediatric high-grade glioma. G207 converted immunologically "cold" tumors to "hot." (Supported by the Food and Drug Administration and others; ClinicalTrials.gov number, NCT02457845.)., (Copyright © 2021 Massachusetts Medical Society.)
Published: 2021
Full Text: View/download PDF

21. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors.

Author: Fiala EM, Jayakumaran G, Mauguen A, Kennedy JA, Bouvier N, Kemel Y, Fleischut MH, Maio A, Salo-Mullen EE, Sheehan M, Arnold AG, Latham A, Carlo MI, Cadoo K, Murkherjee S, Slotkin EK, Trippett T, Glade Bender J, Meyers PA, Wexler L, Dela Cruz FS, Cheung NK, Basu E, Kentsis A, Ortiz M, Francis JH, Dunkel IJ, Khakoo Y, Gilheeney S, Farouk Sait S, Forlenza CJ, Sulis M, Karajannis M, Modak S, Gerstle JT, Heaton TE, Roberts S, Yang C, Jairam S, Vijai J, Topka S, Friedman DN, Stadler ZK, Robson M, Berger MF, Schultz N, Ladanyi M, O'Reilly RJ, Abramson DH, Ceyhan-Birsoy O, Zhang L, Mandelker D, Shukla NN, Kung AL, Offit K, Zehir A, and Walsh MF
Subjects: Child, Genetic Predisposition to Disease, Germ Cells, Humans, Prospective Studies, Germ-Line Mutation genetics, Neoplasms diagnosis
Abstract: The spectrum of germline predisposition in pediatric cancer continues to be realized. Here we report 751 solid tumor patients who underwent prospective matched tumor-normal DNA sequencing and downstream clinical use (clinicaltrials.gov NCT01775072). Germline pathogenic and likely pathogenic (P/LP) variants were reported. One or more P/LP variants were found in 18% (138/751) of individuals when including variants in low, moderate, and high penetrance dominant or recessive genes, or 13% (99/751) in moderate and high penetrance dominant genes. 34% of high or moderate penetrance variants were unexpected based on the patient's diagnosis and previous history. 76% of patients with positive results completed a clinical genetics visit, and 21% had at least one relative undergo cascade testing as a result of this testing. Clinical actionability additionally included screening, risk reduction in relatives, reproductive use, and use of targeted therapies. Germline testing should be considered for all children with cancer.
Published: 2021
Full Text: View/download PDF

22. Neuro-Oncology Training for the Child Neurology Resident.

Author: Malbari F, Partap S, Gust J, Duke E, Sato A, Khakoo Y, and Ullrich NJ
Subjects: Humans, Neurologists education, Pediatrics education, Brain Neoplasms therapy, Internship and Residency methods, Medical Oncology education, Neurology education
Abstract: Neuro-oncology is a rapidly evolving subspecialty that involves the management of patients with primary or metastatic central and peripheral nervous system neoplasms, as well as any other disorders or complications affecting the nervous system that result either directly or indirectly from central nervous system or systemic malignancies and related treatment. Neurologists serve a critical role in the multidisciplinary management of these complex patients. As leaders of the Child Neurology Society Special Interest Group in NeuroOncology, we propose ways to provide sufficient exposure, minimize knowledge gaps, and optimize training experiences in neuro-oncology for child neurology residency programs.
Published: 2021
Full Text: View/download PDF

23. Trainee Award Announcement.

Author: Khakoo Y, Brenton JN, Mytinger JR, Reese JJ Jr, and Scantlebury MH
Subjects: Brain Diseases diagnostic imaging, Humans, Neuroimaging standards, Awards and Prizes, Neurology, Pediatrics
Published: 2020
Full Text: View/download PDF

24. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.

Author: Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, Offer K, Nakajima M, Williams C, Nogués L, Pelissier Vatter FA, Hashimoto A, Davies AE, Freitas D, Kenific CM, Ararso Y, Buehring W, Lauritzen P, Ogitani Y, Sugiura K, Takahashi N, Alečković M, Bailey KA, Jolissant JS, Wang H, Harris A, Schaeffer LM, García-Santos G, Posner Z, Balachandran VP, Khakoo Y, Raju GP, Scherz A, Sagi I, Scherz-Shouval R, Yarden Y, Oren M, Malladi M, Petriccione M, De Braganca KC, Donzelli M, Fischer C, Vitolano S, Wright GP, Ganshaw L, Marrano M, Ahmed A, DeStefano J, Danzer E, Roehrl MHA, Lacayo NJ, Vincent TC, Weiser MR, Brady MS, Meyers PA, Wexler LH, Ambati SR, Chou AJ, Slotkin EK, Modak S, Roberts SS, Basu EM, Diolaiti D, Krantz BA, Cardoso F, Simpson AL, Berger M, Rudin CM, Simeone DM, Jain M, Ghajar CM, Batra SK, Stanger BZ, Bui J, Brown KA, Rajasekhar VK, Healey JH, de Sousa M, Kramer K, Sheth S, Baisch J, Pascual V, Heaton TE, La Quaglia MP, Pisapia DJ, Schwartz R, Zhang H, Liu Y, Shukla A, Blavier L, DeClerck YA, LaBarge M, Bissell MJ, Caffrey TC, Grandgenett PM, Hollingsworth MA, Bromberg J, Costa-Silva B, Peinado H, Kang Y, Garcia BA, O'Reilly EM, Kelsen D, Trippett TM, Jones DR, Matei IR, Jarnagin WR, and Lyden D
Subjects: Animals, Biomarkers, Tumor blood, Cell Line, HSC70 Heat-Shock Proteins metabolism, Humans, Machine Learning, Mice, Mice, Inbred C57BL, Microfilament Proteins metabolism, Neoplasms metabolism, Proteome analysis, Proteome metabolism, Proteomics methods, Sensitivity and Specificity, Tetraspanin 29 metabolism, rap GTP-Binding Proteins metabolism, Biomarkers, Tumor metabolism, Extracellular Vesicles metabolism, Neoplasms diagnosis
Abstract: There is an unmet clinical need for improved tissue and liquid biopsy tools for cancer detection. We investigated the proteomic profile of extracellular vesicles and particles (EVPs) in 426 human samples from tissue explants (TEs), plasma, and other bodily fluids. Among traditional exosome markers, CD9, HSPA8, ALIX, and HSP90AB1 represent pan-EVP markers, while ACTB, MSN, and RAP1B are novel pan-EVP markers. To confirm that EVPs are ideal diagnostic tools, we analyzed proteomes of TE- (n = 151) and plasma-derived (n = 120) EVPs. Comparison of TE EVPs identified proteins (e.g., VCAN, TNC, and THBS2) that distinguish tumors from normal tissues with 90% sensitivity/94% specificity. Machine-learning classification of plasma-derived EVP cargo, including immunoglobulins, revealed 95% sensitivity/90% specificity in detecting cancer. Finally, we defined a panel of tumor-type-specific EVP proteins in TEs and plasma, which can classify tumors of unknown primary origin. Thus, EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type., Competing Interests: Declaration of Interests D.L., A.H., H.S.K., and L.B. have filed a U.S. patent application related to this work., (Copyright © 2020 Elsevier Inc. All rights reserved.)
Published: 2020
Full Text: View/download PDF

25. Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.

Author: Patel A, Fischer C, Lin YC, Basu EM, Kushner BH, De Braganca K, and Khakoo Y
Subjects: Adrenocorticotropic Hormone administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Female, Humans, Immunoglobulins, Intravenous administration & dosage, Infant, Male, Neoplasm Staging, Retrospective Studies, Rituximab administration & dosage, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Neuroblastoma diagnosis, Neuroblastoma mortality, Neuroblastoma therapy, Opsoclonus-Myoclonus Syndrome diagnosis, Opsoclonus-Myoclonus Syndrome mortality, Opsoclonus-Myoclonus Syndrome therapy
Abstract: Objective: To review the treatment and revaccination of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome (OMAS) patients at Memorial Sloan Kettering Cancer Center (MSK)., Procedure: Institutional Review Board approval was obtained for this retrospective study of patients with neuroblastoma-associated OMAS followed at MSK from 2000 to 2016., Results: Fourteen patients (nine female) were 9-21 (median 17) months old at diagnosis of neuroblastoma and OMAS syndrome. They had stage 1 (n = 12), stage 2B, or intermediate-risk stage 4. Tumor histology was favorable in 11 patients, unfavorable in two, and unknown in one patient. No patient had amplified MYCN. All patients underwent tumor resection at diagnosis. Anti-neuroblastoma treatment was limited to chemotherapy in one patient. Overall survival is 100% at 3-16 (median 10) years. For OMAS, 13 patients received intravenous immune globulin (IVIg), adrenocorticotropic hormone (ACTH), and rituximab, and one received ACTH and IVIg. Seven patients experienced OMAS relapse. For these relapses, five patients received low-dose cyclophosphamide and two received rituximab. The mean total OMAS treatment was 20-96 (median 48) months. Seven patients started rituximab ≤3 months from diagnosis and did not relapse. The other six experienced OMAS relapse. To date, six patients have been revaccinated at a minimum of 2 years after completion of OMAS therapy without OMAS recurrence., Conclusions: Patients with neuroblastoma-associated OMAS had excellent overall survival. Early initiation of rituximab, IVIg, and ACTH may reduce risks of OMAS relapse. Revaccination can be resumed without exacerbation of OMAS. Further investigation with a larger cohort of patients is needed., (© 2020 Wiley Periodicals, Inc.)
Published: 2020
Full Text: View/download PDF

26. Medulloblastoma: an Old Diagnosis with New Promises.

Author: Szalontay L and Khakoo Y
Subjects: Cerebellar Neoplasms diagnosis, Clinical Trials as Topic, Humans, Immunotherapy, Medulloblastoma diagnosis, Neoplasm Recurrence, Local, Oncolytic Virotherapy, Risk Assessment, Signal Transduction, Cerebellar Neoplasms therapy, Medulloblastoma therapy
Abstract: Purpose of Review: Molecular subtyping in medulloblastoma (MB) has diagnostic and prognostic values which impact therapy. This paper provides guidance for the clinician caring for pediatric and adult patients with medulloblastoma in the modern era., Recent Findings: Medulloblastoma comprises four molecularly distinct subgroups: wingless activated (WNT), sonic hedgehog activated (SHH), group 3, and group 4. Risk stratification before and after the discovery of molecular subgroups aims at minimizing toxicity by reducing radiation and chemotherapy doses in low-risk patients while maintaining favorable overall survival (OS). The mainstay of newly diagnosed medulloblastoma treatment is surgery, radiation therapy, and chemotherapy, except for children under 6 years of age, where high-dose chemotherapy with autologous stem cell rescue is used to avoid or delay radiotherapy, preventing neurocognitive sequelae. Management of recurrent/refractory medulloblastoma remains a challenge with immunotherapy and small-molecule inhibitors forming the backbone of novel strategies. Recent innovations in medulloblastoma research allow us to better understand pathogenesis and molecular characteristics resulting in advanced risk stratification models, new therapeutic approaches, and overall improved survival and quality of life.
Published: 2020
Full Text: View/download PDF

27. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.

Author: Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Khakoo Y, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, and Brentjens RJ
Subjects: Adolescent, Adult, Child, Child, Preschool, Cytokine Release Syndrome etiology, Cytokine Release Syndrome pathology, Cytokine Release Syndrome prevention & control, Female, Humans, Infant, Male, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local metabolism, Neoplasm, Residual etiology, Neoplasm, Residual pathology, Neoplasm, Residual prevention & control, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes pathology, Neurotoxicity Syndromes prevention & control, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Salvage Therapy, Survival Rate, T-Lymphocytes immunology, Treatment Outcome, Young Adult, Antigens, CD19 metabolism, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes transplantation
Abstract: Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric/young adult patients (age, 1-22.5 years) with R/R B-ALL were treated with 19-28z CAR T cells. Conditioning chemotherapy included high-dose (3 g/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (≤1.5 g/m2) cyclophosphamide (LD-Cy) for 8 patients. Fifteen patients had pretreatment minimal residual disease (MRD; <5% blasts in bone marrow), and 10 patients had pretreatment morphologic evidence of disease (≥5% blasts in bone marrow). All toxicities were reversible, including severe cytokine release syndrome in 16% (4 of 25) and severe neurotoxicity in 28% (7 of 25) of patients. Treated patients were assessed for response, and, among the evaluable patients (n = 24), response and peak CAR T-cell expansion were superior in the HD-Cy/MRD cohorts, as compared with the LD-Cy/morphologic cohorts without an increase in toxicity. Our data support the safety of CD19-specific CAR T-cell therapy for R/R B-ALL. Our data also suggest that dose intensity of conditioning chemotherapy and minimal pretreatment disease burden have a positive impact on response without a negative effect on toxicity. This trial was registered at www.clinicaltrials.gov as #NCT01860937., (© 2019 by The American Society of Hematology.)
Published: 2019
Full Text: View/download PDF

28. The 2018 Pediatric Neurology Trainee Publication Award.

Author: Scher MS, Breningstall G, Gilbert D, Jordan L, Khakoo Y, and LePichon JB
Subjects: Humans, Internship and Residency, Awards and Prizes, Neurology, Pediatrics
Published: 2019
Full Text: View/download PDF

29. Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression.

Author: Schaff LR, Marghoob A, Rosenblum MK, Meyer R, and Khakoo Y
Subjects: Adalimumab therapeutic use, Adolescent, Follow-Up Studies, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases pathology, Magnetic Resonance Imaging methods, Male, Melanosis diagnosis, Melanosis therapy, Meningeal Neoplasms diagnostic imaging, Neurocutaneous Syndromes diagnosis, Neurocutaneous Syndromes therapy, Nevus, Pigmented diagnosis, Nevus, Pigmented pathology, Nevus, Pigmented surgery, Rare Diseases, Risk Assessment, Skin Neoplasms diagnosis, Skin Neoplasms therapy, Tomography, X-Ray Computed methods, Treatment Outcome, Adalimumab adverse effects, Cell Transformation, Neoplastic pathology, Melanosis pathology, Meningeal Neoplasms secondary, Meningeal Neoplasms surgery, Neurocutaneous Syndromes pathology, Skin Neoplasms pathology
Abstract: Neurocutaneous melanosis (NCM) is the condition of abnormal melanocyte deposition in the leptomeninges and brain parenchyma. Associated with congenital melanocytic nevi, NCM can result in neurologic deficits, hydrocephalus, and rarely, malignant transformation of cells. We present the case of a 16-year-old boy with NCM who developed malignant leptomeningeal melanoma following immunosuppression with a TNFα inhibitor. To our knowledge, this is the first reported case of a patient with known NCM undergoing malignant transformation after anti-TNF therapy for inflammatory bowel disease., (© 2019 Wiley Periodicals, Inc.)
Published: 2019
Full Text: View/download PDF

30. GE-13 * A NOVEL ASSOCIATION OF PRIMARY CNS GERMINOMA IN A PATIENT WITH NAIL PATELLA SYNDROME

Author: Hanmantgad, S., primary and Khakoo, Y., additional
Published: 2014
Full Text: View/download PDF

31. Craniospinal Radiation Therapy May Not Be Necessary for Localized Nongerminomatous Germ Cell Tumors (NGGCT)

Author: Cahlon, O., primary, Dunkel, I., additional, Gilheeney, S., additional, Khakoo, Y., additional, Souweidane, M., additional, De Braganca, K., additional, Kramer, K., additional, and Wolden, S., additional
Published: 2014
Full Text: View/download PDF

32. MEDULLOBLASTOMA

Author: Vaidyanathan, G., primary, Gururangan, S., additional, Bigner, D., additional, Zalutsky, M., additional, Morfouace, M., additional, Shelat, A., additional, Megan, J., additional, Freeman, B. B., additional, Robinson, S., additional, Throm, S., additional, Olson, J. M., additional, Li, X.-N., additional, Guy, K. R., additional, Robinson, G., additional, Stewart, C., additional, Gajjar, A., additional, Roussel, M., additional, Sirachainan, N., additional, Pakakasama, S., additional, Anurathapan, U., additional, Hansasuta, A., additional, Dhanachai, M., additional, Khongkhatithum, C., additional, Hongeng, S., additional, Feroze, A., additional, Lee, K.-S., additional, Gholamin, S., additional, Wu, Z., additional, Lu, B., additional, Mitra, S., additional, Cheshier, S., additional, Northcott, P., additional, Lee, C., additional, Zichner, T., additional, Lichter, P., additional, Korbel, J., additional, Wechsler-Reya, R., additional, Pfister, S., additional, Project, I. P. T., additional, Li, K. K.-W., additional, Xia, T., additional, Ma, F. M. T., additional, Zhang, R., additional, Zhou, L., additional, Lau, K.-M., additional, Ng, H.-K., additional, Lafay-Cousin, L., additional, Chi, S., additional, Madden, J., additional, Smith, A., additional, Wells, E., additional, Owens, E., additional, Strother, D., additional, Foreman, N., additional, Packer, R., additional, Bouffet, E., additional, Wataya, T., additional, Peacock, J., additional, Taylor, M. D., additional, Ivanov, D., additional, Garnett, M., additional, Parker, T., additional, Alexander, C., additional, Meijer, L., additional, Grundy, R., additional, Gellert, P., additional, Ashford, M., additional, Walker, D., additional, Brent, J., additional, Cader, F. Z., additional, Ford, D., additional, Kay, A., additional, Walsh, R., additional, Solanki, G., additional, Peet, A., additional, English, M., additional, Shalaby, T., additional, Fiaschetti, G., additional, Baulande, S., additional, Gerber, N., additional, Baumgartner, M., additional, Grotzer, M., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Minami, T., additional, Kanai, N., additional, Yamaguchi, T., additional, Gomi, A., additional, Morimoto, A., additional, Hill, R., additional, Kuijper, S., additional, Lindsey, J., additional, Schwalbe, E., additional, Barker, K., additional, Boult, J., additional, Williamson, D., additional, Ahmad, Z., additional, Hallsworth, A., additional, Ryan, S., additional, Poon, E., additional, Ruddle, R., additional, Raynaud, F., additional, Howell, L., additional, Kwok, C., additional, Joshi, A., additional, Nicholson, S. L., additional, Crosier, S., additional, Wharton, S., additional, Robson, K., additional, Michalski, A., additional, Hargrave, D., additional, Jacques, T., additional, Pizer, B., additional, Bailey, S., additional, Swartling, F., additional, Petrie, K., additional, Weiss, W., additional, Chesler, L., additional, Clifford, S., additional, Kitanovski, L., additional, Prelog, T., additional, Kotnik, B. F., additional, Debeljak, M., additional, Grotzer, M. A., additional, Gevorgian, A., additional, Morozova, E., additional, Kazantsev, I., additional, Iukhta, T., additional, Safonova, S., additional, Kumirova, E., additional, Punanov, Y., additional, Afanasyev, B., additional, Zheludkova, O., additional, Grajkowska, W., additional, Pronicki, M., additional, Cukrowska, B., additional, Dembowska-Baginska, B., additional, Lastowska, M., additional, Murase, A., additional, Nobusawa, S., additional, Gemma, Y., additional, Yamazaki, F., additional, Masuzawa, A., additional, Uno, T., additional, Osumi, T., additional, Shioda, Y., additional, Kiyotani, C., additional, Mori, T., additional, Matsumoto, K., additional, Ogiwara, H., additional, Morota, N., additional, Hirato, J., additional, Nakazawa, A., additional, Terashima, K., additional, Fay-McClymont, T., additional, Walsh, K., additional, Mabbott, D., additional, Sturm, D., additional, Northcott, P. A., additional, Jones, D. T. W., additional, Korshunov, A., additional, Pfister, S. M., additional, Kool, M., additional, Hooper, C., additional, Hawes, S., additional, Kees, U., additional, Gottardo, N., additional, Dallas, P., additional, Siegfried, A., additional, Bertozzi, A. I., additional, Sevely, A., additional, Loukh, N., additional, Munzer, C., additional, Miquel, C., additional, Bourdeaut, F., additional, Pietsch, T., additional, Dufour, C., additional, Delisle, M. B., additional, Kawauchi, D., additional, Rehg, J., additional, Finkelstein, D., additional, Zindy, F., additional, Phoenix, T., additional, Gilbertson, R., additional, Trubicka, J., additional, Borucka-Mankiewicz, M., additional, Ciara, E., additional, Chrzanowska, K., additional, Perek-Polnik, M., additional, Abramczuk-Piekutowska, D., additional, Jurkiewicz, D., additional, Luczak, S., additional, Kowalski, P., additional, Krajewska-Walasek, M., additional, Sheila, C., additional, Lee, S., additional, Foster, C., additional, Manoranjan, B., additional, Pambit, M., additional, Berns, R., additional, Fotovati, A., additional, Venugopal, C., additional, O'Halloran, K., additional, Narendran, A., additional, Hawkins, C., additional, Ramaswamy, V., additional, Taylor, M., additional, Singhal, A., additional, Hukin, J., additional, Rassekh, R., additional, Yip, S., additional, Singh, S., additional, Duhman, C., additional, Dunn, S., additional, Chen, T., additional, Rush, S., additional, Fuji, H., additional, Ishida, Y., additional, Onoe, T., additional, Kanda, T., additional, Kase, Y., additional, Yamashita, H., additional, Murayama, S., additional, Nakasu, Y., additional, Kurimoto, T., additional, Kondo, A., additional, Sakaguchi, S., additional, Fujimura, J., additional, Saito, M., additional, Arakawa, T., additional, Arai, H., additional, Shimizu, T., additional, Jurkiewicz, E., additional, Daszkiewicz, P., additional, Drogosiewicz, M., additional, Hovestadt, V., additional, Buchhalter, I., additional, Jager, N. N., additional, Stuetz, A., additional, Johann, P., additional, Schmidt, C., additional, Ryzhova, M., additional, Landgraf, P., additional, Hasselblatt, M., additional, Schuller, U., additional, Yaspo, M.-L., additional, von Deimling, A., additional, Eils, R., additional, Modi, A., additional, Patel, M., additional, Berk, M., additional, Wang, L.-x., additional, Plautz, G., additional, Camara-Costa, H., additional, Resch, A., additional, Lalande, C., additional, Kieffer, V., additional, Poggi, G., additional, Kennedy, C., additional, Bull, K., additional, Calaminus, G., additional, Grill, J., additional, Doz, F., additional, Rutkowski, S., additional, Massimino, M., additional, Kortmann, R.-D., additional, Lannering, B., additional, Dellatolas, G., additional, Chevignard, M., additional, Solecki, D., additional, McKinnon, P., additional, Olson, J., additional, Hayden, J., additional, Ellison, D., additional, Buss, M., additional, Remke, M., additional, Lee, J., additional, Caspary, T., additional, Castellino, R., additional, Sabel, M., additional, Gustafsson, G., additional, Fleischhack, G., additional, Benesch, M., additional, Navajas, A., additional, Reddingius, R., additional, Delisle, M.-B., additional, Lafon, D., additional, Sevenet, N., additional, Pierron, G., additional, Delattre, O., additional, Ecker, J., additional, Oehme, I., additional, Mazitschek, R., additional, Lodrini, M., additional, Deubzer, H. E., additional, Kulozik, A. E., additional, Witt, O., additional, Milde, T., additional, Patmore, D., additional, Boulos, N., additional, Wright, K., additional, Boop, S., additional, Janicki, T., additional, Burzynski, S., additional, Burzynski, G., additional, Marszalek, A., additional, Triscott, J., additional, Green, M., additional, Rassekh, S. R., additional, Toyota, B., additional, Dunham, C., additional, Dunn, S. E., additional, Liu, K.-W., additional, Pei, Y., additional, Genovesi, L., additional, Ji, P., additional, Davis, M., additional, Ng, C. G., additional, Cho, Y.-J., additional, Jenkins, N., additional, Copeland, N., additional, Wainwright, B., additional, Tang, Y., additional, Schubert, S., additional, Nguyen, B., additional, Masoud, S., additional, Lee, A., additional, Willardson, M., additional, Bandopadhayay, P., additional, Bergthold, G., additional, Atwood, S., additional, Whitson, R., additional, Qi, J., additional, Beroukhim, R., additional, Tang, J., additional, Oro, A., additional, Link, B., additional, Bradner, J., additional, Vallero, S. G., additional, Bertin, D., additional, Basso, M. E., additional, Milanaccio, C., additional, Peretta, P., additional, Cama, A., additional, Mussano, A., additional, Barra, S., additional, Morana, G., additional, Morra, I., additional, Nozza, P., additional, Fagioli, F., additional, Garre, M. L., additional, Darabi, A., additional, Sanden, E., additional, Visse, E., additional, Stahl, N., additional, Siesjo, P., additional, Vaka, D., additional, Vasquez, F., additional, Weir, B., additional, Cowley, G., additional, Keller, C., additional, Hahn, W., additional, Gibbs, I. C., additional, Partap, S., additional, Yeom, K., additional, Martinez, M., additional, Vogel, H., additional, Donaldson, S. S., additional, Fisher, P., additional, Perreault, S., additional, Guerrini-Rousseau, L., additional, Pujet, S., additional, Kieffer-Renaux, V., additional, Raquin, M. A., additional, Varlet, P., additional, Longaud, A., additional, Sainte-Rose, C., additional, Valteau-Couanet, D., additional, Staal, J., additional, Lau, L. S., additional, Zhang, H., additional, Ingram, W. J., additional, Cho, Y. J., additional, Hathout, Y., additional, Brown, K., additional, Rood, B. R., additional, Handler, M., additional, Hankinson, T., additional, Kleinschmidt-Demasters, B. K., additional, Hutter, S., additional, Jones, D. T., additional, Kagawa, N., additional, Hirayama, R., additional, Kijima, N., additional, Chiba, Y., additional, Kinoshita, M., additional, Takano, K., additional, Eino, D., additional, Fukuya, S., additional, Yamamoto, F., additional, Nakanishi, K., additional, Hashimoto, N., additional, Hashii, Y., additional, Hara, J., additional, Yoshimine, T., additional, Wang, J., additional, Guo, C., additional, Yang, Q., additional, Chen, Z., additional, Filipek, I., additional, Swieszkowska, E., additional, Tarasinska, M., additional, Perek, D., additional, Kebudi, R., additional, Koc, B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Wolff, J., additional, Darendeliler, E., additional, Kerl, K., additional, Gronych, J., additional, McGlade, J., additional, Endersby, R., additional, Hii, H., additional, Johns, T., additional, Sastry, J., additional, Murphy, D., additional, Ronghe, M., additional, Cunningham, C., additional, Cowie, F., additional, Jones, R., additional, Calisto, A., additional, Sangra, M., additional, Mathieson, C., additional, Brown, J., additional, Phuakpet, K., additional, Larouche, V., additional, Bartels, U., additional, Ishida, T., additional, Hasegawa, D., additional, Miyata, K., additional, Ochi, S., additional, Saito, A., additional, Kozaki, A., additional, Yanai, T., additional, Kawasaki, K., additional, Yamamoto, K., additional, Kawamura, A., additional, Nagashima, T., additional, Akasaka, Y., additional, Soejima, T., additional, Yoshida, M., additional, Kosaka, Y., additional, von Bueren, A., additional, Goschzik, T., additional, Kortmann, R., additional, von Hoff, K., additional, Friedrich, C., additional, Muehlen, A. z., additional, Warmuth-Metz, M., additional, Soerensen, N., additional, Deinlein, F., additional, Zwiener, I., additional, Faldum, A., additional, Kuehl, J., additional, KRAMER, K., additional, -Taskar, N. P., additional, Zanzonico, P., additional, Humm, J. L., additional, Wolden, S. L., additional, Cheung, N.-K. V., additional, Venkataraman, S., additional, Alimova, I., additional, Harris, P., additional, Birks, D., additional, Balakrishnan, I., additional, Griesinger, A., additional, Foreman, N. K., additional, Vibhakar, R., additional, Margol, A., additional, Robison, N., additional, Gnanachandran, J., additional, Hung, L., additional, Kennedy, R., additional, Vali, M., additional, Dhall, G., additional, Finlay, J., additional, Erdrich-Epstein, A., additional, Krieger, M., additional, Drissi, R., additional, Fouladi, M., additional, Gilles, F., additional, Judkins, A., additional, Sposto, R., additional, Asgharzadeh, S., additional, Peyrl, A., additional, Chocholous, M., additional, Holm, S., additional, Grillner, P., additional, Blomgren, K., additional, Azizi, A., additional, Czech, T., additional, Gustafsson, B., additional, Dieckmann, K., additional, Leiss, U., additional, Slavc, I., additional, Babelyan, S., additional, Dolgopolov, I., additional, Pimenov, R., additional, Mentkevich, G., additional, Gorelishev, S., additional, Laskov, M., additional, von Bueren, A. O., additional, Nowak, J., additional, Kortmann, R. D., additional, Mynarek, M., additional, Muller, K., additional, Gerber, N. U., additional, Ottensmeier, H., additional, Kwiecien, R., additional, Yankelevich, M., additional, Boyarshinov, V., additional, Glekov, I., additional, Ozerov, S., additional, Gorelyshev, S., additional, Popa, A., additional, Subbotina, N., additional, Martin, A. M., additional, Nirschl, C., additional, Polanczyk, M., additional, Bell, R., additional, Martinez, D., additional, Sullivan, L. M., additional, Santi, M., additional, Burger, P. C., additional, Taube, J. M., additional, Drake, C. G., additional, Pardoll, D. M., additional, Lim, M., additional, Li, L., additional, Wang, W.-G., additional, Pu, J.-X., additional, Sun, H.-D., additional, Ruggieri, R., additional, Symons, M. H., additional, Vanan, M. I., additional, Bolin, S., additional, Schumacher, S., additional, Zeid, R., additional, Yu, F., additional, Vue, N., additional, Gibson, W., additional, Paolella, B., additional, Swartling, F. J., additional, Kieran, M. W., additional, Bradner, J. E., additional, Maher, O., additional, Khatua, S., additional, Tarek, N., additional, Zaky, W., additional, Gupta, T., additional, Mohanty, S., additional, Kannan, S., additional, Jalali, R., additional, Kapitza, E., additional, Denkhaus, D., additional, Muhlen, A. z., additional, van Vuurden, D. G., additional, Garami, M., additional, Fangusaro, J., additional, Davidson, T. B., additional, da Costa, M. J. G., additional, Sterba, J., additional, Clifford, S. C., additional, Finlay, J. L., additional, Schmidt, R., additional, Felsberg, J., additional, Skladny, H., additional, Cremer, F., additional, Reifenberger, G., additional, Kunder, R., additional, Sridhar, E., additional, Moiyadi, A. A., additional, Goel, A., additional, Goel, N., additional, Shirsat, N., additional, Othman, R., additional, Storer, L., additional, Kerr, I., additional, Coyle, B., additional, Law, N., additional, Smith, M. L., additional, Greenberg, M., additional, Laughlin, S., additional, Malkin, D., additional, Liu, F., additional, Moxon-Emre, I., additional, Scantlebury, N., additional, Nasir, A., additional, Onion, D., additional, Lourdusamy, A., additional, Grabowska, A., additional, Cai, Y., additional, Bradshaw, T., additional, de Medeiros, R. S. S., additional, Beaugrand, A., additional, Soares, S., additional, Epelman, S., additional, Wang, W., additional, Sultan, M., additional, Wechsler-Reya, R. J., additional, Zapatka, M., additional, Radlwimmer, B., additional, Alderete, D., additional, Baroni, L., additional, Lubinieki, F., additional, Auad, F., additional, Gonzalez, M. L., additional, Puya, W., additional, Pacheco, P., additional, Aurtenetxe, O., additional, Gaffar, A., additional, Gros, L., additional, Cruz, O., additional, Calvo, C., additional, Shinojima, N., additional, Nakamura, H., additional, Kuratsu, J.-i., additional, Hanaford, A., additional, Eberhart, C., additional, Archer, T., additional, Tamayo, P., additional, Pomeroy, S., additional, Raabe, E., additional, De Braganca, K., additional, Gilheeney, S., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Dunkel, I., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Shih, D., additional, Wang, X., additional, Faria, C., additional, Raybaud, C., additional, Tabori, U., additional, Rutka, J., additional, Jacobs, S., additional, De Vathaire, F., additional, Diallo, I., additional, Llanas, D., additional, Verez, C., additional, Diop, F., additional, Kahlouche, A., additional, Puget, S., additional, Thompson, E., additional, Prince, E., additional, Amani, V., additional, Sin-Chan, P., additional, Lu, M., additional, Kleinman, C., additional, Spence, T., additional, Picard, D., additional, Ho, K. C., additional, Chan, J., additional, Majewski, J., additional, Jabado, N., additional, Dirks, P., additional, Huang, A., additional, Madden, J. R., additional, Donson, A. M., additional, Mirsky, D. M., additional, Dubuc, A., additional, Mack, S., additional, Gendoo, D., additional, Luu, B., additional, MacDonald, T., additional, Van Meter, T., additional, Croul, S., additional, Laureano, A., additional, Brugmann, W., additional, Denman, C., additional, Singh, H., additional, Huls, H., additional, Moyes, J., additional, Sandberg, D., additional, Silla, L., additional, Cooper, L., additional, and Lee, D., additional
Published: 2014
Full Text: View/download PDF

33. HIGH GRADE GLIOMAS AND DIPG

Author: Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional
Published: 2014
Full Text: View/download PDF

34. New insights into neurocutaneous melanosis.

Author: Jakchairoongruang K, Khakoo Y, Beckwith M, and Barkovich AJ
Subjects: Adolescent, Child, Child, Preschool, Contrast Media, Female, Humans, Infant, Infant, Newborn, Male, Melanosis pathology, Neurocutaneous Syndromes pathology, Retrospective Studies, Young Adult, Magnetic Resonance Imaging methods, Melanosis diagnostic imaging, Neurocutaneous Syndromes diagnostic imaging
Abstract: Background: Neurocutaneous melanosis is a rare disorder in which children with large cutaneous melanotic nevi have associated melanosis in the brain. Although many affected children have structurally normal brains, some have associated developmental disorders or brain anomalies., Objectives: To determine the range of extent of brain melanosis as assessed by magnetic resonance imaging (MRI) and to investigate the frequency and types of associated brain anomalies., Materials and Methods: We retrospectively reviewed brain and spine MRIs of 80 patients with congenital melanocytic nevi (range: 1 day to 22 years of age) affiliated with Nevus Outreach Inc. from 1998 to 2017. Central nervous system (CNS) melanosis was diagnosed when a mass with abnormal parenchymal T1 hyperintensity was seen. The locations of abnormal signal, associated malformations, the presence of contrast enhancement and, in patients with more than one MRI, changes over time were recorded. Associations among findings were analyzed using chi-square test or Fisher exact test., Results: Brain abnormalities were identified in 33 patients. The most common finding was melanosis in the amygdala, which was found in 31 patients (an isolated finding in 14 patients). Nineteen patients had melanosis in the brainstem, cerebellum, cerebral cortex or thalamus. Cerebral and/or spinal leptomeningeal enhancement was uncommon (five patients). Hindbrain melanosis was associated with cerebellar and pontine hypoplasia (P=0.012). Brain melanosis was most easily seen on T1 images prior to myelination; reduced/loss of visibility was noted as the CNS matured., Conclusion: Brain melanosis is a common manifestation in children with large cutaneous melanotic nevi, most commonly found in the anterior temporal lobes (amygdala), brainstem, cerebellum and cerebral cortex. Hindbrain melanosis is associated with hypoplasia of the affected structures. Early imaging is optimal to provide the greatest sensitivity for diagnosis and to guide proper management.
Published: 2018
Full Text: View/download PDF

35. The 2017 Pediatric Neurology Training Publication Award.

Author: Scher MS, Breningstall G, Gilbert D, Jordan L, Khakoo Y, and LePichon JB
Subjects: Child, History, 21st Century, Humans, Neurology, Pediatrics, Publishing, Awards and Prizes, Periodicals as Topic
Published: 2018
Full Text: View/download PDF

36. The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.

Author: Basu D, Salgado CM, Bauer B, Khakoo Y, Patel JR, Hoehl RM, Bertolini DM, Zabec J, Brzozowski MR, and Reyes-Múgica M
Subjects: Apoptosis drug effects, Cell Proliferation drug effects, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Female, Humans, Infant, Melanoma etiology, Melanoma metabolism, Melanoma pathology, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Pyridazines, Signal Transduction, Skin Neoplasms etiology, Skin Neoplasms metabolism, Skin Neoplasms pathology, Tumor Cells, Cultured, Tumor Stem Cell Assay, Cell Transformation, Neoplastic drug effects, Melanoma prevention & control, Melanosis complications, Neurocutaneous Syndromes complications, Phosphoinositide-3 Kinase Inhibitors, Quinolines pharmacology, Skin Neoplasms prevention & control, Sulfonamides pharmacology, TOR Serine-Threonine Kinases antagonists & inhibitors
Abstract: Background: Omipalisib has been found to affect the viability of cancer cells. However, its effect on clonogenicity - a feature of cancer stem cells, is not clear. Cells isolated from neurocutaneous melanocytosis (NCM) patients' lesions grow clonogenically. The aim of this study was to investigate the effect of omipalisib treatment on clonogenic growth of NCM cells in vitro., Materials and Methods: Clonogenic growth efficiency was evaluated by colony formation assays with or without specific growth factors. Activation of MEK and Akt was determined by immunoblots. Colony formation and cell viability were assessed upon pharmacological inhibition of MEK, Akt and mToR., Results: Clonogenicity appeared to depend on bFGF and IGF1signaling through ERK and Akt. Omipalisib treatment prevented colony formation and induced autophagic cell death., Conclusion: Signaling through Akt is important for survival of clonogenic cells in NCM, and omipalisib treatment as a monotherapy or in combination with MEK162 could be an effective therapeutic strategy to inhibit clonogenic growth., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Published: 2018
Full Text: View/download PDF

37. Patterns of relapse for children with localized intracranial ependymoma.

Author: De B, Khakoo Y, Souweidane MM, Dunkel IJ, Patel SH, Gilheeney SW, De Braganca KC, Karajannis MA, and Wolden SL
Subjects: Adolescent, Brain Neoplasms epidemiology, Child, Child, Preschool, Disease Management, Ependymoma epidemiology, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Recurrence, Retrospective Studies, Survival Analysis, Treatment Outcome, Young Adult, Brain Neoplasms physiopathology, Brain Neoplasms therapy, Ependymoma physiopathology, Ependymoma therapy
Abstract: We examined patterns of relapse and prognostic factors in children with intracranial ependymoma. Records of 82 children diagnosed with localized intracranial ependymoma were reviewed. 52% first presented to our institution after relapse. Median age at initial diagnosis was 4 years (range 0-18 years). Gender was 55% male. Initial tumor location was infratentorial in 71% and supratentorial in 29%. Histology was WHO Grade II in 32% and Grade III in 68%. As part of definitive management, 99% had surgery, 70% received RT (26% 2D/3D-conformal RT[CRT], 22% intensity-modulated RT [IMRT], 22% proton), and 37% received chemotherapy. Median follow-up was 4.6 years (range 0.2-32.9). Overall, 74% of patients relapsed (50% local, 17% distant, 7% local + distant) at a median 1.5 (range 0.1-17.5) years. Five-year OS and FFS for patients presenting prior to relapse are 70% (95% confidence interval [CI], 50-83%) and 48% (95% CI 30-64%), respectively. On log-rank, superior overall survival (OS) was demonstrated for gross total resection (p = 0.03). Superior failure-free survival (FFS) was demonstrated for age < 5 years (p = 0.04). No difference in OS or FFS was found between 2D/3D-CRT versus IMRT/proton (p > 0.05). On multivariate analysis, age ≤ 5 was independently associated with a lower risk of death and failure versus older patients (p < 0.05). Contrary to previous reports, young age may not be a poor prognostic factor in patients who can tolerate intensive treatment. Future studies examining patients stratified by clinical and molecular attributes are warranted.
Published: 2018
Full Text: View/download PDF

38. Rapid autopsy of a patient with recurrent anaplastic ependymoma.

Author: Lange KR, Fischer C, Rajappa P, Connors S, Pisapia D, Greenfield JP, Beltran H, Rubin M, Mosquera JM, and Khakoo Y
Subjects: Cause of Death, Child, Preschool, Death, Female, Hospice Care methods, Hospice Care trends, Humans, Magnetic Resonance Imaging methods, Autopsy methods, Ependymoma pathology, Time Factors
Abstract: ABSTRACTObjective:Our aim was to outline a procedure for obtaining a rapid autopsy in order to collect high-quality postmortem tissue for genomic analysis., Methods: This report details a bi-institutional collaborative effort to coordinate a rapid autopsy for a pediatric patient who had died at home. We discuss the scientific rationale for offering a rapid autopsy to caregivers of pediatric patients as well as parental perspectives on broaching the subject of autopsy. We then review the logistics and coordination involved with planning a rapid autopsy and the sequence of events needed to maximize tissue quality., Results: We report the successful coordination of a rapid autopsy for a patient who died in a hospice setting at her out-of-state home. The time interval from death to the start of the rapid autopsy procedure was 4.5 hours, despite the logistical considerations demanded by the location of the patient. Tumor aliquots and nonneoplastic tissues were successfully snap frozen for downstream genomic studies., Significance of Results: Physicians should consider trialing a rapid autopsy program at their institution that could be offered to caregivers of pediatric patients. This case report offers a framework to help clinicians develop their own rapid autopsy programs as well as guidelines to help streamline this process for appropriate candidates going forward.
Published: 2018
Full Text: View/download PDF

39. Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma.

Author: Kushner BH and Khakoo Y
Subjects: Ataxia, Child, Humans, Immunoglobulins, Intravenous, Neuroblastoma, Opsoclonus-Myoclonus Syndrome, Prednisone
Published: 2018
Full Text: View/download PDF

40. Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.

Author: De B, Beal K, De Braganca KC, Souweidane MM, Dunkel IJ, Khakoo Y, Gilheeney SW, DeAngelis LM, Menzel P, Patel SH, and Wolden SL
Subjects: Adolescent, Adult, Aged, Disease Progression, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Treatment Outcome, Young Adult, Cerebellar Neoplasms diagnosis, Cerebellar Neoplasms radiotherapy, Medulloblastoma diagnosis, Medulloblastoma radiotherapy
Abstract: Medulloblastoma (MB) is rare in adults and treatment guidelines are consequently not well-established. Few modern series have reported long-term follow-up and treatment sequelae. We examined long-term outcomes of adult MB patients at one institution. Records of 29 consecutive patients (18 male, 11 female) aged ≥ 18 years who received radiotherapy (RT) for primary MB from 1990 to 2016 were reviewed. Median age at diagnosis was 28 years (range 18-72 years). Seventeen patients were standard risk and 12 were high risk. Nineteen patients had gross total resection, seven had subtotal resection, and three had biopsy only. Median craniospinal irradiation and boost doses were 36 Gy (range 23.4-39.6 Gy) and 55.8 Gy (range 54-59.4 Gy), respectively. Of 24 patients receiving chemotherapy, 20 received concurrent + adjuvant and 4 received adjuvant only. At median follow-up of 9.0 years (range 1.1-20.5 years), five patients recurred: four in the posterior fossa and one in both the posterior fossa and above the tentorium. Five patients died: two of disease progression and three after possible treatment complications (seizure, lobar pneumonia, and multifactorial sepsis). At last follow-up, 23 patients were alive with no evidence of disease. Long-term effects include executive dysfunction (n = 17), weakness/ataxia (n = 16), and depression/anxiety (n = 13). Kaplan-Meier estimates of 10-year overall survival and failure-free survival are 83% (95% confidence interval [CI] 59-93%) and 79% (CI 55-91%), respectively. Despite encouraging disease control in this cohort, long-term sequelae may limit quality of life. Multimodality pediatric regimens using lower RT doses may be considered to reduce treatment-related morbidity.
Published: 2018
Full Text: View/download PDF

41. A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Author: Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, and Cheung NV
Subjects: Adolescent, Adult, Cerebellar Neoplasms cerebrospinal fluid, Cerebellar Neoplasms diagnostic imaging, Cerebellar Neoplasms mortality, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Infant, Injections, Intraventricular, Male, Medulloblastoma cerebrospinal fluid, Medulloblastoma diagnostic imaging, Medulloblastoma mortality, Survival Rate, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antineoplastic Agents, Immunological administration & dosage, Cerebellar Neoplasms radiotherapy, Iodine Radioisotopes administration & dosage, Medulloblastoma radiotherapy, Radioimmunotherapy
Abstract: Background: High-risk and recurrent medulloblastoma (MB) is associated with significant mortality. The murine monoclonal antibody 3F8 targets the cell-surface disialoganglioside GD2 on MB. We tested the efficacy, toxicity, and dosimetry of compartmental radioimmunotherapy (cRIT) with intraventricular 131 I-labeled 3F8 in patients with MB on a phase II clinical trial., Methods: Patients with histopathologically confirmed high-risk or recurrent MB were eligible for cRIT. After determining adequate cerebrospinal fluid (CSF) flow, patients received 2 mCi (where Ci is Curie) 124 I-3F8 or 131 I-3F8 with nuclear imaging for dosimetry, followed by up to four therapeutic (10 mCi/dose) 131 I-3F8 injections. Dosimetry estimates were based on serial CSF and blood samplings over 48 hr plus region-of-interest analyses on serial imaging scans. Disease evaluation included pre- and posttherapy brain/spine magnetic resonance imaging approximately every 3 months for the first year after treatment, and every 6-12 months thereafter., Results: Forty-three patients received a total of 167 injections; 42 patients were evaluable for outcome. No treatment-related deaths occurred. Toxicities related to drug administration included acute bradycardia with somnolence, headache, fatigue, and CSF pleocytosis consistent with chemical meningitis and dystonic reaction. Total CSF absorbed dose was 1,453 cGy (where Gy is Gray; 350.0-2,784). Median overall survival from first dose of cRIT was 24.9 months (95% confidence interval [CI]:16.3-55.8). Patients treated in radiographic and cytologic remission were at a lower risk of death compared to patients with radiographically measurable disease (hazard ratio: 0.40, 95% CI: 0.18-0.88, P = 0.024)., Conclusions: cRIT with 131 I-3F8 is safe, has favorable dosimetry to CSF, and when added to salvage therapy using conventional modalities, may have clinical utility in maintaining remission in high-risk or recurrent MB., (© 2017 Wiley Periodicals, Inc.)
Published: 2018
Full Text: View/download PDF

42. A 16-year-old transplant patient with amnesia, insomnia, and visual hallucinations

Author: Graber, J. J., primary, Kernan, N. A., additional, and Khakoo, Y., additional
Published: 2013
Full Text: View/download PDF

43. CLIN-PEDIATRICS CLINICAL RESEARCH

Author: Packer, R. J., primary, Rood, B. R., additional, Onar-Thomas, A., additional, Goldman, S., additional, Fisher, M. J., additional, Smith, C., additional, Boyett, J., additional, Kun, L., additional, Nelson, M. B., additional, Compton, P., additional, Macey, P., additional, Patel, S., additional, Jacob, E., additional, O'Neil, S., additional, Finlay, J., additional, Harper, R., additional, Legault, G., additional, Chhabra, A., additional, Allen, J. C., additional, Si, S. J., additional, Flores, N., additional, Haley, K., additional, Malvar, J., additional, Fangusaro, J., additional, Dhall, G., additional, Sposto, R., additional, Davidson, T. B., additional, Finlay, J. L., additional, Krieger, M., additional, Zhou, T., additional, Miller, D. C., additional, Geyer, J. R., additional, Pollack, I. F., additional, Gajjar, A., additional, Cohen, B. H., additional, Nellan, A., additional, Murray, J. C., additional, Honeycutt, J., additional, Gomez, A., additional, Head, H., additional, Braly, E., additional, Puccetti, D. M., additional, Patel, N., additional, Kennedy, T., additional, Bradley, K., additional, Howard, S., additional, Salamat, S., additional, Iskandar, B., additional, Slavc, I., additional, Peyrl, A., additional, Chocholous, M., additional, Kieran, M., additional, Azizi, A., additional, Czech, T., additional, Dieckmann, K., additional, Haberler, C., additional, Sadighi, Z. S., additional, Ellezam, B., additional, Khatua, S., additional, Ater, J., additional, Biswas, A., additional, Kakkar, A., additional, Goyal, S., additional, Mallick, S., additional, Sarkar, C., additional, Sharma, M. C., additional, Julka, P. K., additional, Rath, G. K., additional, Glass, T., additional, Cochrane, D. D., additional, Rassekh, S. R., additional, Goddard, K., additional, Hukin, J., additional, Deopujari, C. E., additional, Khakoo, Y., additional, Hanmantgad, S., additional, Forester, K., additional, McDonald, S. A., additional, De Braganca, K., additional, Yohay, K., additional, Wolff, J. E., additional, Kwiecien, R., additional, Rutkowski, S., additional, Pietsch, T., additional, Faldum, A., additional, Kortmann, R.-D., additional, Kramm, C., additional, Fouladi, M., additional, Olson, J., additional, Stewart, C., additional, Kocak, M., additional, Wagner, L., additional, Packer, R., additional, Gururangan, S., additional, Blaney, S., additional, Pollack, I., additional, Demuth, T., additional, Gilbertson, R., additional, Powell, M. K., additional, Klement, G. L., additional, Roffidal, T., additional, and Fonkem, E., additional
Published: 2012
Full Text: View/download PDF

44. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Author: Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional
Published: 2012
Full Text: View/download PDF

45. RADIOLOGY

Author: Murray, J., primary, Braly, E., additional, Head, H., additional, Donahue, D., additional, Rush, S., additional, Stence, N., additional, Liu, A., additional, Kleinhenz, J., additional, Bison, B., additional, Pietsch, T., additional, von Hoff, K., additional, von Bueren, A., additional, Rutkowski, S., additional, Warmuth-Metz, M., additional, Jaspan, T., additional, Brisse, H., additional, Potepan, P., additional, Berg, F., additional, Gerber, N., additional, Sugiyama, K., additional, Kurisu, K., additional, Kajiwara, Y., additional, Takayasu, T., additional, Saito, T., additional, Hanaya, R., additional, Yamasaki, F., additional, Vicente, J., additional, Fuster-Garcia, E., additional, Tortajada, S., additional, Garcia-Gomez, J. M., additional, Davies, N., additional, Natarajan, K., additional, Wilson, M., additional, Grundy, R. G., additional, Wesseling, P., additional, Monleon, D., additional, Celda, B., additional, Robles, M., additional, Peet, A. C., additional, Perret, C., additional, Boltshauser, E., additional, Scheer, I., additional, Kellenberger, C., additional, Grotzer, M., additional, Steffen-Smith, E., additional, Venzon, D., additional, Bent, R., additional, Baker, E., additional, Shandilya, S., additional, Warren, K., additional, Shih, C.-S., additional, West, J., additional, Ho, C., additional, Porter, D., additional, Wang, Y., additional, Saykin, A., additional, McDonald, B., additional, Arfanakis, K., additional, Vezina, G., additional, Hargrave, D., additional, Poussaint, T. Y., additional, Goldman, S., additional, Packer, R., additional, Wen, P., additional, Pollack, I., additional, Zurakowski, D., additional, Kun, L., additional, Prados, M., additional, Kieran, M., additional, Eckel, L., additional, Keating, G., additional, Giannini, C., additional, Wetjen, N., additional, Patton, A., additional, Sarlls, J., additional, Pierpaoli, C., additional, Walker, L., additional, Perreault, S., additional, Lober, R., additional, Yeom, K., additional, Carret, A.-S., additional, Vogel, H., additional, Partap, S., additional, Fisher, P., additional, Gill, S. K., additional, Davies, N. P., additional, MacPherson, L., additional, Arvanitis, T. N., additional, Gill, S., additional, Arvanitis, T., additional, Peet, A., additional, Hayes, L., additional, Jones, R., additional, Mazewski, C., additional, Aguilera, D., additional, Palasis, S., additional, Bendel, A., additional, Patterson, R., additional, Petronio, J., additional, Meijer, L., additional, Grundy, R. G. G., additional, Walker, D. A., additional, Robison, N., additional, Grant, F., additional, Treves, S. T., additional, Bandopadhayay, P., additional, Manley, P., additional, Chi, S., additional, Zimmerman, M. A., additional, Chordas, C., additional, Goumnerova, L., additional, Smith, E., additional, Scott, M., additional, Ullrich, N. J., additional, Poussaint, T., additional, Yang, J. C., additional, Lightner, D. D., additional, Khakoo, Y., additional, Wolden, S. L., additional, Smee, R., additional, Zhao, C., additional, Spencer-Trotter, B., additional, Hallock, A., additional, Konski, A., additional, Bhambani, K., additional, Mahajan, A., additional, Jones, J., additional, Ketonen, L., additional, Paulino, A., additional, Ater, J., additional, Grosshans, D., additional, Dauser, R., additional, Weinberg, J., additional, Chintagumpala, M., additional, Dvir, R., additional, Elhasid, R., additional, Corn, B., additional, Tempelhoff, H., additional, Matceyevsky, D., additional, Makrin, V., additional, Shtraus, N., additional, Yavetz, D., additional, Constantini, S., additional, Gez, E., additional, Yu, E.-S., additional, Kim, Y.-J., additional, Park, H. J., additional, Kim, H. J., additional, Shin, S. H., additional, Kim, J.-H., additional, Kim, J.-Y., additional, Lee, Y. K., additional, Fiore, M. R., additional, Sanne, C., additional, Mandeville, H. C., additional, Saran, F. H., additional, Greenspoon, J., additional, Duckworth, J., additional, Singh, S., additional, Scheinemann, K., additional, Whitton, A., additional, Gauvain, K., additional, Geller, T., additional, Elbabaa, S., additional, Dombrowski, J., additional, Wong, K., additional, Olch, A., additional, Davidson, T. B., additional, Venkatramani, R., additional, Haley, K., additional, Zaky, W., additional, Dhall, G., additional, Finlay, J., additional, Bishop, M. W., additional, Hummel, T. R., additional, Leach, J., additional, Minturn, J., additional, Breneman, J., additional, Stevenson, C., additional, Wagner, L., additional, Sutton, M., additional, Miles, L., additional, and Fouladi, M., additional
Published: 2012
Full Text: View/download PDF

46. GERM CELL TUMORS

Author: Yang, Q.-y., primary, Chen, Z.-p., additional, Hayase, T., additional, Gomi, A., additional, Higaki, A., additional, Kawahara, Y., additional, Kobari, T., additional, Fukuda, T., additional, Kashii, Y., additional, Morimoto, A., additional, Sakatani, T., additional, Momoi, M. Y., additional, Murray, M., additional, Hale, J., additional, Heinemann, K., additional, Saran, F., additional, Calaminus, G., additional, Nicholson, J., additional, Martinez, S., additional, Khakoo, Y., additional, Gilheeney, S., additional, Kramer, K., additional, Wolden, S., additional, Souweidane, M., additional, Dunkel, I., additional, Brichtova, E., additional, Pavelka, Z., additional, Bobekova, A., additional, Magnova, O., additional, Kren, L., additional, Svoboda, T., additional, Sprlakova, A., additional, Slampa, P., additional, Zitterbart, K., additional, Sterba, J., additional, Campen, C. J., additional, Ashby, D., additional, Fisher, P. G., additional, Monje, M., additional, Dagri, J., additional, Torkildson, J., additional, Cheng, J., additional, Wang, R. X., additional, Yock, T., additional, Banerjee, A., additional, Dhall, G., additional, Finlay, J., additional, Yanagisawa, T., additional, Fukuoka, K., additional, Suzuki, T., additional, Kohga, T., additional, Wakiya, K., additional, Adachi, J., additional, Mishima, K., additional, Fujimaki, T., additional, Matsutani, M., additional, Nishikawa, R., additional, Frappaz, D., additional, Kortmann, R. D., additional, Alapetite, C., additional, Garre, M. L., additional, Ricardi, U., additional, Saran, F. H., additional, Czech, T., additional, Walker, R., additional, Koga, T., additional, Legault, G., additional, Allen, J., additional, Geludkova, O., additional, Mushinskaya, M., additional, Kushel, Y., additional, Korshunov, A., additional, Melikyan, A., additional, Shishkina, L., additional, Oserova, V., additional, Oserov, S., additional, Maserkina, N., additional, Borodina, I., additional, Kumirova, E., additional, Boyarchuk, N., additional, Gorbatyh, S., additional, Popova, E., additional, Sherbenko, O., additional, Zelinskaya, N., additional, Shammasov, R., additional, Privalova, L., additional, Chulkov, O., additional, Kosel, Y., additional, Cappellano, A. M., additional, Paiva, P., additional, Cavalheiro, S., additional, Dastoli, P., additional, Seixas, M. T., additional, Silva, N. S., additional, Chan, G. C.-F., additional, Shing, M. M.-K., additional, Yuen, H.-L., additional, Li, R. C.-H., additional, Li, C.-K., additional, Ha, S.-Y., additional, Chen, H.-H., additional, Chang, F.-C., additional, Chen, Y.-W., additional, Wong, T.-T., additional, Yarascavitch, B., additional, Stein, N., additional, Ribeiro, L., additional, Whitton, A., additional, Duckworth, J., additional, Scheinemann, K., additional, Singh, S., additional, Ozerov, S., additional, Gorelyshev, S., additional, Trunin, Y., additional, Kagawa, N., additional, Fujimoto, Y., additional, Hirayama, R., additional, Chiba, Y., additional, Kijima, N., additional, Arita, H., additional, Kinoshita, M., additional, Hashimoto, N., additional, Maruno, M., additional, Yoshimine, T., additional, Guerra, G. P., additional, Oscanoa, M., additional, Cavero, L., additional, Yabar, A., additional, Ugarte, E., additional, Trivedi, M., additional, Tyagi, A., additional, Goodden, J., additional, Chumas, P., additional, Elliott, M., additional, Picton, S., additional, Robison, N., additional, Prabhu, S., additional, Sun, P., additional, Chi, S., additional, Kieran, M., additional, Manley, P., additional, Cohen, L., additional, Goumnerova, L., additional, Smith, E., additional, Scott, M., additional, London, W., additional, and Ullrich, N. J., additional
Published: 2012
Full Text: View/download PDF

47. Hemangioma of the cavernous sinus in a child

Author: Litkowski, P., primary, Khakoo, Y., additional, Gilheeney, S., additional, Souweidane, M., additional, Huse, J., additional, Haque, S., additional, and Young, R. J., additional
Published: 2011
Full Text: View/download PDF

48. A Retrospective Study of Re-irradiation (Re-RT) for Recurrent Medulloblastoma (MB)

Author: Bakst, R.L., primary, Dunkel, I., additional, Gilheeney, S., additional, Khakoo, Y., additional, Becher, O., additional, Souweidane, M., additional, and Wolden, S., additional
Published: 2010
Full Text: View/download PDF

49. Phase I study of single-agent perifosine for recurrent pediatric solid tumors.

Author: Becher, O. J., primary, Trippett, T. M., additional, Kolesar, J., additional, Gilheeney, S., additional, Jiang, Z., additional, Khakoo, Y., additional, Lyden, D., additional, Sima, C., additional, Holland, E. C., additional, and Dunkel, I. J., additional
Published: 2010
Full Text: View/download PDF

50. Outcomes using IMRT Tumor-bed Boost for Medulloblastoma

Author: Polkinghorn, W.R., primary, Dunkel, I.J., additional, Souweidane, M.M., additional, Khakoo, Y., additional, Lyden, D.C., additional, Gershon, T.R., additional, Gilheeney, S.W., additional, Chen, W.C., additional, and Wolden, S.L., additional
Published: 2008
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Category

Publication Type

Journal

Region

Database

Publisher

1,095 results on '"Khakoo Y"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources